Medicofarma BiotechWAR:MDB -2.70%33 Quick Ratio is 0.96 as of Mar. 2026, which is 22% above its 10-year median of 0.79. GuruFocus rates WAR:MDB with a GF Score™ of 33/100 and a GF Value™ of zł0.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 997 Drug Manufacturers companies, Medicofarma Biotech ranks worse than 68.1% on this metric.
Medicofarma Biotech has a quick ratio of 0.96. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Medicofarma Biotech's Quick Ratio or its related term are showing as below:
WAR:MDB'
s Quick Ratio Range Over the Past 10 Years
Min: 0.18 Med: 0.79 Max: 1.68
Current: 0.96
During the past 13 years, Medicofarma Biotech's highest Quick Ratio was 1.68. The lowest was 0.18. And the median was 0.79.
WAR:MDB's Quick Ratio is ranked worse than 68.1% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs WAR:MDB: 0.96
Medicofarma Biotech (WAR:MDB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Medicofarma Biotech Quick Ratio Related Terms
Medicofarma Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Medicofarma Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MDB vs ZTS, UTHR, VTRS: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicofarma Biotech Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Medicofarma Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Medicofarma Biotech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicofarma Biotech (WAR:MDB) has a Quick Ratio of 0.96 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Medicofarma Biotech and its competitors. This is 22% above median its historical median of 0.79. Over the past decade, Medicofarma Biotech's Quick Ratio has ranged from 0.18 to 1.68. According to the industry distribution chart, Medicofarma Biotech ranks #679 out of 997 companies in the Drug Manufacturers industry, placing it in the top 68.1%.
Is Medicofarma Biotech's Quick Ratio too high?
Medicofarma Biotech's current Quick Ratio of 0.96 is 22% above median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.68. The Drug Manufacturers industry median Quick Ratio is 1.45. Medicofarma Biotech's value of 0.96 is 33.8% below this industry median. Based on the distribution chart, Medicofarma Biotech ranks #679 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medicofarma Biotech has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicofarma Biotech ranks #679 out of 997 companies for Quick Ratio. This places Medicofarma Biotech in the lower half of its industry. The industry median Quick Ratio is 1.45. Medicofarma Biotech's value of 0.96 is 33.8% below this benchmark. Historically, Medicofarma Biotech's own Quick Ratio has ranged from 0.18 to 1.68 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 1.45, Medicofarma Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicofarma Biotech's current Quick Ratio of 0.96 is 33.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Medicofarma Biotech and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicofarma Biotech's current Quick Ratio is 0.96, which is 22% above median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.05, compared to a current price of zł0.43 — trading 764% above its estimated fair value. The current Quick Ratio is 0.96, which is 22% above median its 10-year median of 0.79 and 33.8% below the Drug Manufacturers industry median of 1.45. Medicofarma Biotech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Quick Ratio is 0.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?
Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued.
The current stock price of zł0.43 is trading 764% above its estimated GF Value™ of zł0.05.
GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.
Key valuation signals for WAR:MDB:
Quick Ratio: 0.96 (22% above median its 10-year median of 0.79)
GF Value™: zł0.05 vs. price of zł0.43 (764% above fair value)
Industry Position: 33.8% below the Drug Manufacturers median (#679 of 997)
No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
33GF Score
Get the complete analysis for WAR:MDB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDB has been successfully added to your 
